Lacosamida Intas

Lacosamide, the active ingredient in Lacosamida Intas, is a sodium channel blocker presented as an oral tablet for oral use. It treats partial‑onset seizures in adults and adolescents. GNH USA supplies Lacosamida Intas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is used to manage seizure disorders that involve abnormal neuronal firing.

Partial‑onset seizures: reduces seizure frequency in focal epilepsy. Adjunctive therapy for focal seizures: enhances control when added to existing antiepileptic regimens. Monotherapy for focal epilepsy: may be used alone to manage seizure activity.

Lacosamide may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Blurred vision - Diplopia

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including anaphylaxis - Elevated liver enzymes - Blood dyscrasias such as agranulocytosis

When prescribing lacosamide, clinicians should consider several safety aspects.

Dose adjustment in renal impairment: reduce dose based on renal function. Monitor cardiac conduction in patients with heart disease: check ECG for PR changes. Avoid abrupt discontinuation: taper to prevent seizure worsening. Use caution in hepatic impairment: monitor liver function tests. Pregnancy and breastfeeding: safety unknown, weigh risks and benefits. Store at ambient temperature: keep in original packaging, protect from moisture.

Lacosamide can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Drugs that prolong PR interval (e.g., class IA antiarrhythmics): risk of cardiac conduction delay. - Other sodium‑channel blockers (e.g., phenytoin): may enhance CNS depression.

Moderate Interactions (Monitor Closely): - Carbamazepine (enzyme inducer): may reduce lacosamide concentrations. - Oral contraceptives: potential reduction in contraceptive efficacy. - Alcohol or CNS depressants: additive dizziness or sedation.